Denosumab biosimilar by Sandoz Group for Humoral Hypercalcemia of Malignancy: Likelihood of Approval

Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Humoral Hypercalcemia of Malignancy.

Geriatric Assessment, QoL Correlate With OS in Older Patients with Pancreatic Cancer

SAN FRANCISCO — Older patients’ survival in metastatic pancreatic cancer had a significant association with baseline vulnerabilities and quality-of-life (QoL) factors, beyond performance status, data

January 27, 2025

Biogen signs molecular glue deal, raises yearly projections

Is 2024 the year of molecular glues? Biogen on Tuesday became the latest company to partner on the increasingly popular subject, teaming up with private

October 31, 2024

Rheum Patients on HCQ: Stick With It or Face Heart Consequences

High levels of adherence to prescribed antimalarial drugs for lupus and rheumatoid arthritis (RA) was associated with markedly lower cardiovascular event rates in one Canadian

September 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.